The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment

Author:

Lam Brian P.1,Jeffers Thomas1,Younoszai Zahra1,Fazel Yousef1,Younossi Zobair M.2

Affiliation:

1. Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA

2. Betty and Guy Beatty Center for Integrated Research, Claude Moore Health Education and Research Building, 3300 Gallows Road, Falls Church, VA 22042, USA

Abstract

Chronic hepatitis C (CHC) affects over 185 million individuals worldwide, approximately 3% of the world’s population. CHC can lead to quality of life impairment, cirrhosis, hepatocellular carcinoma (HCC), liver failure and liver-related death. While CHC has been associated with increases in HCC, liver-related mortality and all-cause mortality, being cured of CHC is associated with improvement in these outcomes. Older interferon-based regimens were complex and toxic and required 6–12 months of therapy, with cure rates averaging around 40–45% for HCV genotype 1. Newer interferon-free regimens are now available in the US, Europe, Japan and in other countries. These regimens have short durations, minimal side effects, low pill burden and efficacy approaching 90–100%. We may eventually see single-tablet regimens lasting no more than 4–6 weeks. This review will summarize the data regarding these interferon-free regimens, including Gilead’s Harvoni (sofosbuvir/ledipasvir), AbbVie’s Viekira Pak (paritaprevir/ritonavir/ombitasvir with dasabuvir), and Janssen’s Olysio (simeprevir) with sofosbuvir. Some practical considerations as we move into an interferon-free era will also be discussed, such as patient adherence and drug–drug interactions.

Publisher

SAGE Publications

Subject

Gastroenterology

Reference43 articles.

1. AbbVie Inc. (2015a) Viekira Pak (prescribing information). North Chicago, Illinois: AbbVie Inc.

2. AbbVie Ltd (2015b) Exviera (prescribing information). Maidenhead, UK: AbbVie Ltd.

3. AbbVie Ltd (2015c) Viekirax (prescribing information). Maidenhead, UK: AbbVie Ltd.

4. Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection

5. Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3